Incidence of second primary malignancies in patients with thyroid cancer in the Turkish population
Incidence of second primary malignancies in patients with thyroid cancer in the Turkish population
Background/aim: Thyroid cancer is the most common endocrine malignancy. Recently the incidence has been increasing fastercompared to other malignancies. Different studies have shown that the incidence of breast cancer in patients followed due to thyroidcancer has increased, and vice versa. The aim of this study was to evaluate the frequency of second primary cancers in the follow-up ofpatients with thyroid cancer.Materials and methods: In this study, 1196 patients with thyroid cancer were evaluated in the Necmettin Erbakan University MeramMedical School’s Department of Endocrinology between 2004 and 2018. Demographic characteristics and radiological and pathologicalresults of the patients were recorded. The presence of accompanying second malignancies in patients with thyroid cancer was investigated.Results: In our study, 985 (82.4%) women (mean age: 46.1 ± 13.3 years) and 211 (17.6%) men (mean age: 49.9 ± 14.2 years) wereevaluated. The median follow-up was 63 months (2–164 months). Of the 1196 patients, 1126 (94.1%) had no additional cancer and 70(5.9%) patients had a second malignancy. The accompanying second malignancies were breast cancer in 24 (2%) patients, skin cancerin 8 (0.7%) patients, renal cell cancer in 5 (0.4%) patients, lung cancer in 5 (0.4%) patients, colon cancer in 5 (0.4%) patients, lymphomain 5 (0.4%) patients, endometrial cancer in 4 (0.3%) patients, and 14 cases of other rare types of cancer.Conclusion: In our study, it was found that the most common second primary malignancy in patients with thyroid cancer was breastcancer. However, other cancers (skin cancer, renal cell cancer, lymphoma, and colon, lung, or endometrial cancer) may occur in patientswith thyroid cancer.
___
- 1. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016; 388 (10061): 2783-2795. doi: 10.1016/S0140- 6736(16)30172-6
- 2. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J et al. Cancer Incidence in Five Continents. No. 160. Vol. 9. Lyon, France: IARC; 2007.
- 3. Mazzaferri EL. Thyroid cancer. In Becker KL (editor). Principles and Practice of Endocrinology and Metabolism, 3rd Ed. Philadelphia, PA, USA: Lippincott, Williams & Wilkins; 2001. pp. 382-402.
- 4. Sherman SI. Thyroid carcinoma. Lancet 2003; 361 (9356): 501- 511. doi: 10.1016/s0140-6736(03)12488-9
- 5. Rosenberg SA. Cancer of the endocrine system. In: Devita VT, Hellman S, Rosenberg SA (editors). Cancer: Principles and Practice of Oncology. 8th Ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2008. pp. 1655-1682.
- 6. Fang Yu, Jinhua M, Huo K, Li P. Association between breast cancer and thyroid cancer: a descriptive study. Translational Cancer Research 2017; 6 (2): 393-401. doi: 10.21037/ tcr.2017.03.44
- 7. Sandeep TC, Strachan MWJ, Reynolds RM, Brewster DH, Scélo G et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. Journal of Clinical Endocrinology and Metabolism 2006; 91: 1819-1825. doi: 10.1210/jc.2005-2009
- 8. Ronckers C, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. International Journal of Cancer 2005; 117 (2): 281-288. doi: 10.1002/ijc.21064
- 9. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS et al. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. American Journal of Epidemiology 1988; 127 (5): 969-980. doi: 10.1093/ oxfordjournals.aje.a114900
- 10. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M et al. CHEK2 is a multiorgan cancer susceptibility gene. American Journal of Human Genetics 2004; 75 (6): 1131- 1135. doi: 10.1086/426403
- 11. Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. International Journal of Oncology 2010; 36 (5): 1067-1080. doi: 10.3892/ ijo_00000588
- 12. Silva-Vieira M, Carrilho Vaz S, Esteves S, Ferreira TC, Limbert E et al. Second primary cancer in patients with differentiated thyroid cancer: does radioiodine play a role? Thyroid 2017; 27 (8): 1068-1076. doi: 10.1089/thy.2016.0655
- 13. Izkhakov E, Barchana M, Liphshitz I, Silverman BG, Stern N et al. Trends of second primary malignancy in patients with thyroid cancer: a population-based cohort study in Israel. Thyroid 2017; 27 (6): 793-801. doi: 10.1089/thy.2016.0481
- 14. Nielsen SM, White MG, Hong S, Aschebrook-Kilfoy B, Kaplan EL et al. The breast-thyroid cancer link: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention 2016; 25 (2): 231-238. doi: 10.1158/1055-9965.EPI15-0833
- 15. GLOBOCAN. Turkey Source: New Global Cancer Data. Lyon, France: GLOBOCAN; 2018.
- ISSN: 1300-0144
- Yayın Aralığı: Yılda 6 Sayı
- Yayıncı: TÜBİTAK
Sayıdaki Diğer Makaleler
Mehmet ERDOĞAN, Kemal ÜRETEN, Mustafa ÖZBEK, Erdem AKBAL
Hanane ZAHIR, Jihane BELKHIR, Hanane MOUHIB, Mustapha Ait AMEUR, Mohammed CHAKOUR
Alper DEVECİ, Yahya Can DURA, Deniz Sözmen CILIZ, Güzelali ÖZDEMİR, Enver KILIÇ, Erman CEYHAN, Burak KULAKOĞLU, Sualp TURAN
Taner SARAK, Muhammed KARADENİZ
Ben Zheng ZHOU, Da Hu ZHANG, Wei Min YU, Jin Zhuo NING
Emrah AKAY, Onur IŞIK, Ayşen Yaprak ENGİN, Volkan ÇAKIR
Nevreste Didem Sonbay YILMAZ, Cem SAKA, Burcu ARSLAN, Nurdan Aygener YEŞİLYURT, Dilek SAKA, Sadik ARDIÇ, İstemihan AKIN
Melia KARAKÖSE, İlker ÇORDAN, Mustafa CAN, Muhammet KOCABAŞ, Mustafa KULAKSIZOĞLU, Feridun KARAKURT
Emrah SALMAN, Salih ÇETİNER, Bariş BORAL, Filiz KİBAR, Eren ERKEN, Emine Duygu ERSÖZLÜ, Suade Özlem BADAK, Reyhan Bilici SALMAN, Yaşar SERTDEMİR, Alev Çetin DURAN, Akgün YAMAN
Özgür ÇİÇEKLİ, Erhan ŞÜKÜR, Alauddin KOCHAİ, Levent BAYAM, İzzet BİNGÖL, Uğur ÖZDEMİR